Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, reposted from ICMR-NIRBID on LinkedIn:
”Reposting with immense pride and gratitude
Truly delighted to see our ‘Factor VIII Inhibitor Point-of-Care Diagnostic’ successfully transferred at Science–Tech’ on National Technology Day 2026.
Grateful to my wonderful team – Sharda Shanbhag, Sweta Kaskar, and Moni Singh – and honoured that this milestone was achieved in the presence of Hon’ble Minister Dr Jitendra Singh .
Proud to see this innovation licensed to Meril Pvt Ltd – bringing us a step closer to accessible and affordable hemophilia diagnostics.”
Quoting ICMR-National Institute for Research on Blood and Immune Disorders, (ICMR-NIRBID)‘s post:
”ICMR–NIRBID is especially proud to highlight the successful technology transfer of its novel ‘Factor VIII Inhibitor Point-of-Care Diagnostic’, developed by Rucha Patil, Sharda Shanbhag, Sweta Kaskar, and Moni Singh, at the national programme Science–Tech’ held on the occasion of National Technology Day 2026 at BRIC–National Institute of Immunology, in the presence of Jitendra Singh, Hon’ble Minister of State (Independent Charge), Ministry of Science and Technology and Ministry of Earth Sciences; MoS, PMO; Ministry of Personnel, Public Grievances and Pensions; Department of Atomic Energy; and Department of Space, Government of India.
This innovation has been licensed to Meril Life Sciences, marking a significant advancement toward enhancing accessible and timely diagnostics for hemophilia care.
The novel FVIII inhibitor POCT is a low-cost, point-of-care lateral flow assay based on gold nanoparticle technology, enabling rapid detection of FVIII inhibitors at approximately one-twentieth the cost of the gold-standard assay, while remaining unaffected by non-factor therapies.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy